The native
ligand for the
G protein-coupled
bombesin receptor subtype-3 (BRS-3) has currently not been identified. Studies in mice showed robust
BRS-3 expression in the hypothalamic satiety centers, and genetic receptor inactivation resulted in
obesity, diabetes, and
hypertension.
BRS-3 was also detected in normal human pancreatic islet cells suggesting a critical role of
BRS-3 in regulating energy metabolism and satiety via central and peripheral mechanisms of action. The
cyclic AMP response element binding protein (CREB) is a main regulator of pancreatic β-cell gene expression required for
glucose homeostasis and islet cell survival, and hypothalamic regulation of satiety. Therefore, in this study we examined whether agonist-dependent hBRS-3 stimulation mediates CREB activation. A selective hBRS-3
peptide agonist and two non-selective hBRS-3
peptide agonists were used to activate ectopically expressed hBRS-3. Stimulation with hBRS-3
peptide agonists resulted in transient
calcium mobilization, whereby the selective
peptide agonist acted exclusively via hBRS-3 but not through the
gastrin-releasing peptide receptor (GRP-R). A selective high-affinity GRP-R antagonist did not inhibit hBRS-3-mediated
calcium signals. We also found time-dependent CREB phosphorylation in response to the selective hBRS-3 activation, which was abrogated by pretreatment with
protein kinase A and
protein kinase C inhibitors. Human
BRS-3 agonists also stimulated CREB transactivation and resulted in modest increases of CRE-dependent gene transcription. These changes were significantly reduced after pretreatment with inhibitors of PKA, PKC, and MEK-1. Thus, our results suggest that hBRS-3 agonist-dependent signaling mediates CREB phosphorylation and transactivation through partially PKA, PKC, and MEK-1 pathways.